CHU Toulouse
CHU Toulouse
Toulouse, France19 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| "Evaluation of the Efficacy of Intravenous Lidocaine on Chronic Post-operative Pain in Patients Requiring Emergency Abdominal Surgery. A Multicentre, Randomised, Controlled, Double-blind Study." | Chronic Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Not yet recruiting | Phase 3 | 2026-10-09 | NCT07869173 | |
| A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | Branch Vein Occlusion, Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, central retinal vein occlusion, diabetic macular edema, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Active, not recruiting | Not stated | 2026-10-02 | NCT05476926 | |
| A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06260163 | |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoid syndrome, carcinoid tumor, carcinoma, cecum neuroendocrine tumor G1, enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor, epithelial neoplasm, ileal neuroendocrine tumor G1, intestinal neuroendocrine tumor G1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, serotonin syndrome | Recruiting | Phase 3 | 2026-09-15 | NCT07087054 | |
| CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity | Arm Injuries, injury | Active, not recruiting | Not stated | 2026-09-10 | NCT06245772 | |
| Impact of Early, Personalized Nutritional Management on 1-month Mortality After Acute Stroke | Stroke, Acute, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-09-01 | NCT07065929 | |
| Sudden Cardiac Arrest Related to Sport in Young and Value of the Genetic Assessment: a French Prospective Register | Death, Death, Sudden, Death, Sudden, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiac arrest, cardiovascular disorder, heart disorder, sudden cardiac arrest | Recruiting | Not stated | 2026-08-25 | NCT06642168 | |
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-08-12 | NCT04307576 | |
| Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | Small Cell Lung Cancer Extensive Stage | Active, not recruiting | Phase 2 | 2026-08-11 | NCT05856695 | |
| Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Not stated | 2026-07-09 | NCT07048795 | |
| Cohort of Patients With Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-05-19 | NCT07512882 | |
| ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach | Amyotrophic Lateral Sclerosis, Sporadic, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, amyotrophic lateral sclerosis type 1, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Not stated | 2026-03-27 | NCT05928416 | |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-03-17 | NCT06353022 | |
| Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus | Skin and Connective Tissue Diseases, autoimmune disease, immune system disorder, pemphigus, skin disorder, vesiculobullous skin disease | Recruiting | Phase 4 | 2026-02-20 | NCT05898308 | |
| Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis | Recurrent Aphtous Stomatitis | Recruiting | Phase 3 | 2026-02-17 | NCT04227314 | |
| Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns | burn, injury | Recruiting | Phase 3 | 2025-11-18 | NCT06968559 | |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2025-11-18 | NCT05781308 | |
| Observatory of Patients With Haemophilia B Treated by IdElvion® | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Not stated | 2025-01-08 | NCT05086575 | |
| FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, pulmonary large cell neuroendocrine carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2024-08-02 | NCT06393816 |